VHCP Management II as of Dec. 31, 2016
Portfolio Holdings for VHCP Management II
VHCP Management II holds 22 positions in its portfolio as reported in the December 2016 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Avexis | 23.7 | $49M | 1.0M | 47.73 | |
| BioCryst Pharmaceuticals (BCRX) | 18.4 | $38M | 6.1M | 6.33 | |
| Edge Therapeutics | 11.6 | $24M | 1.9M | 12.50 | |
| Dbv Technologies | 9.0 | $19M | 374k | 50.04 | |
| Ascendis Pharma A S (ASND) | 7.0 | $15M | 721k | 20.24 | |
| Audentes Therapeutics | 4.0 | $8.2M | 459k | 17.97 | |
| Ra Pharmaceuticals | 4.0 | $8.2M | 543k | 15.19 | |
| Cytomx Therapeutics (CTMX) | 3.0 | $6.4M | 578k | 10.99 | |
| Colucid Pharmaceuticals | 2.8 | $5.8M | 159k | 36.40 | |
| Axovant Sciences | 2.6 | $5.3M | 430k | 12.42 | |
| Heron Therapeutics (HRTX) | 2.5 | $5.3M | 406k | 13.10 | |
| Coherus Biosciences (CHRS) | 1.8 | $3.6M | 130k | 28.15 | |
| D Stemline Therapeutics | 1.6 | $3.4M | 316k | 10.70 | |
| Alcobra | 1.6 | $3.2M | 1.5M | 2.10 | |
| ARCA biopharma | 1.5 | $3.1M | 1.1M | 2.85 | |
| Akari Therapeutics | 1.2 | $2.6M | 370k | 7.04 | |
| Ocera Therapeutics | 1.2 | $2.6M | 1.2M | 2.10 | |
| Lipocine | 0.7 | $1.5M | 420k | 3.68 | |
| Aeglea Biotherapeutics | 0.7 | $1.5M | 350k | 4.35 | |
| Kalvista Pharmaceuticals (KALV) | 0.6 | $1.3M | 222k | 5.96 | |
| Adverum Biotechnologies | 0.4 | $812k | 280k | 2.90 | |
| Pronai Therapeutics | 0.1 | $195k | 131k | 1.49 |
